In 2007, Specialty Tier-Eligible Drugs Accounted for 10 Percent of Part D Spending

We found that specialty tier-eligible drugs accounted for about 10 percent,  or $5.6 billion, of the $54.4 billion in total prescription drug spending under  Part D MA-PD and PDP plans in 2007. 2.) their cost sharing is largely paid by Medicare. While only 8 percent of Part D beneficiaries in MA-PD and PDP plans who  filed claims but did not use any specialty tier-eligible drugs reached the  catastrophic coverage threshold of the Part D benefit in 2007, 55 percent  of beneficiaries who used at least one specialty tier-eligible drug reached  the threshold. Differences in Plans’ Cost-Sharing Structures Result in Out-of-Pocket Costs for Most Beneficiaries That Vary Initially and Then Become Similar

For most beneficiaries—those who are responsible for paying the full cost- sharing amounts required by their plans—who use a given specialty tier- eligible drug, different cost-sharing structures can be expected to result in  varying out-of-pocket costs during the benefit’s initial coverage period. However, as long as beneficiaries reach the catastrophic coverage  threshold in a calendar year—as 31 percent of beneficiaries who used at  least one specialty tier-eligible drug and who were responsible for the full  cost-sharing amounts did in 2007—their annual out-of-pocket costs for  that drug are likely to be similar regardless of their plans’ cost-sharing  structures. 3.) There are several reasons for this. Variations in Negotiated Drug Prices Affect Out-of- Pocket Costs for Most Beneficiaries

For most beneficiaries—those who are responsible for paying the full cost- sharing amounts required by their plans—variations in negotiated drug  prices affect out-of-pocket costs during the initial coverage phase if their  plans require them to pay coinsurance. As the following examples illustrate, there are variations  in negotiated prices between drugs, across plans for the same drug, and  from year to year. Variations between drugs: In 2009—across our sample of 35 plans— beneficiaries who took the cancer drug Gleevec for the entire year could  have been expected to pay about $6,300 out of pocket because Gleevec  had an average negotiated price of about $45,500 per year, while  beneficiaries could have been expected to pay about $10,500 out of pocket  over the entire year if they took the Gaucher disease drug Zavesca, which  had an average negotiated price of about $130,000 per year. For example, the average  negotiated price for a 1-year supply of Gleevec across our sample of plans  increased by 46 percent, from about $31,200 in 2006 to about $45,500 in  2009. Correspondingly, the average out-of-pocket cost for a beneficiary  taking Gleevec for an entire year could have been expected to rise from  about $4,900 in 2006 to more than $6,300 in 2009. Plan Sponsors Report Three Main Reasons Why They Have a Limited Ability to Negotiate Price Concessions for Specialty Tier-Eligible Drugs

The eight Part D plan sponsors we interviewed told us that they have little  leverage in negotiating price concessions for most specialty tier-eligible  drugs. Additionally, all seven of the plan sponsors we surveyed reported  that they were unable to obtain price concessions from manufacturers on  8 of the 20 specialty tier-eligible drugs in our sample between 2006 and  2008. First, they stated that pharmaceutical manufacturers  have little incentive to offer price concessions when a given drug has few  competitors on the market, as is the case for drugs used to treat cancer. In contrast, plan  sponsors told us that they were more often able to negotiate price  concessions for drugs in classes where there are more competing drugs on  the market—such as for drugs used to treat rheumatoid arthritis, multiple  sclerosis, and anemia. However, many  specialty tier-eligible drugs belong to one of the six classes of clinical  concern for which CMS requires Part D plan sponsors to include all or  substantially all drugs on their formularies, eliminating formulary  exclusion as a source of negotiating leverage. Third, plan sponsors told us that they have limited ability to negotiate  price concessions for certain specialty tier-eligible drugs because they  account for a relatively limited share of total prescription drug utilization  among Part D beneficiaries. CMS agreed with portions of our findings and suggested additional  information for us to include in our report. We incorporated comments  from CMS and the plan sponsors as appropriate in our January 2010  report.
Why GAO Did This Study

The Centers for Medicare & Medicaid Services (CMS) allows Part D plans to utilize different tiers with different levels of cost sharing as a way of managing drug utilization and spending. One such tier, the specialty tier, is designed for high-cost drugs whose prices exceed a certain threshold set by CMS. Beneficiaries who use these drugs typically face higher out-of-pocket costs than beneficiaries who use only lower-cost drugs. This testimony is based on GAO's January 2010 report entitled Medicare Part D: Spending, Beneficiary Cost Sharing, and Cost-Containment Efforts for High-Cost Drugs Eligible for a Specialty Tier (GAO-10-242) in which GAO examined, among other things, (1) Part D spending on these drugs in 2007, the most recent year for which claims data were available; (2) how different cost-sharing structures could be expected to affect beneficiary out-of-pocket costs; (3) how negotiated drug prices could be expected to affect beneficiary out-of-pocket costs; and (4) information Part D plan sponsors reported on their ability to negotiate price concessions. For the second and third of these objectives, this testimony focuses on out-of-pocket costs for beneficiaries responsible for paying the full cost-sharing amounts required by their plans. GAO examined CMS data and interviewed officials from CMS and 8 of the 11 largest plan sponsors, based on enrollment in 2008. Seven of the 11 plan sponsors provided price concession data for a sample of 20 drugs for 2006 through 2008.

What GAO Found

High-cost drugs eligible for a specialty tier commonly include immunosuppressant drugs, those used to treat cancer, and antiviral drugs. Specialty tier-eligible drugs accounted for 10 percent, or $5.6 billion, of the $54.4 billion in total prescription drug spending under Medicare Part D plans in 2007. Medicare beneficiaries who received a low-income subsidy (LIS) accounted for most of the spending on specialty tier-eligible drugs-- $4.0 billion, or 70 percent of the total. Among all beneficiaries who used at least one specialty tier-eligible drug in 2007, 55 percent reached the catastrophic coverage threshold, after which Medicare pays at least 80 percent of all drug costs. In contrast, only 8 percent of all Part D beneficiaries who filed claims but did not use any specialty tier-eligible drugs reached this threshold in 2007. Most beneficiaries are responsible for paying the full cost-sharing amounts required by their plans. For such beneficiaries who use a given specialty tier-eligible drug, different cost-sharing structures result in varying out-of-pocket costs only until they reach the catastrophic coverage threshold, which 31 percent of these beneficiaries did in 2007. After that point, beneficiaries' annual out-of-pocket costs for a given drug are likely to be similar regardless of their plans' cost-sharing structures. Variations in negotiated drug prices can also affect out-of-pocket costs for beneficiaries who are responsible for paying the full cost-sharing amounts required by their plans. Variations in negotiated prices can occur between drugs, across plans for the same drug, and from year to year. For example, the average negotiated price for the cancer drug Gleevec across our sample of plans increased by 46 percent between 2006 and 2009, from about $31,200 per year to about $45,500 per year. Correspondingly, the average out-of-pocket cost for a beneficiary taking Gleevec for the entire year could have been expected to rise from about $4,900 in 2006 to more than $6,300 in 2009. Plan sponsors reported having little leverage to negotiate price concessions from manufacturers for most specialty tier-eligible drugs. One reason for this limited leverage was that many of these drugs have few competitors on the market. Plan sponsors reported that they were more often able to negotiate price concessions for drugs with more competitors on the market--such as for drugs used to treat rheumatoid arthritis. Two additional reasons cited for limited negotiating leverage were CMS requirements that plans include all or most drugs from certain therapeutic classes on their formularies, limiting sponsors' ability to exclude drugs from their formularies in favor of competing drugs; and that the relatively limited share of total prescription drug utilization among Part D beneficiaries for some specialty tier-eligible drugs was insufficient to entice manufacturers to offer price concessions. CMS provided GAO with comments on a draft of the January 2010 report. CMS agreed with portions of GAO's findings and suggested additional information for GAO to include in the report, which GAO incorporated as appropriate.